Cost effectiveness of trastuzumab in adjuvant treatment of early breast cancer: A model based analysis

被引：0
|
作者：
Dedes, Konstantin J.
Szucs, Thomas D.
Imesch, Patrick
Fehr, Mathias K.
Fink, Daniel
机构：
[1] Univ Zurich Hosp, Div Gynecol, CH-8091 Zurich, Switzerland
[2] Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Letrozole in the Extended Adjuvant Treatment of Women with Early Breast Cancer
    Khalid El Ouagari
    Jon Karnon
    Thomas Delea
    Willena Talbot
    Jane Brandman
    Breast Cancer Research and Treatment, 2007, 101 : 37 - 49
  • [32] Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer
    El Ouagari, Khalid
    Karnon, Jon
    Delea, Thomas
    Talbot, Willena
    Brandman, Jane
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (01) : 37 - 49
  • [33] Exemestane in adjuvant treatment of early breast cancer in postmenopausal women: results of a UK cost-effectiveness model
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 151 - 151
  • [34] Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer
    Konishi, Takaaki
    Fujiogi, Michimasa
    Michihata, Nobuaki
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1115 - 1123
  • [35] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [36] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [37] A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB REGIMENS IN EARLY HER2/NEU-POSITIVE BREAST CANCER IN COLOMBIA
    Buendia Rodriguez, J. A.
    Vallejos, C.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [38] Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
    Garrison, Louis P., Jr.
    Babigumira, Joseph
    Tournier, Clement
    Goertz, Hans-Peter
    Lubinga, Solomon J.
    Perez, Edith A.
    VALUE IN HEALTH, 2019, 22 (04) : 408 - 415
  • [39] COST EFFECTIVENESS OF ADJUVANT CYCLOPHOSPHAMIDE IN THE TREATMENT OF BREAST CANCER IN SPAIN
    Walter, E.
    Brennig, C.
    Schoellbauer, V
    VALUE IN HEALTH, 2011, 14 (07) : A455 - A455
  • [40] COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA
    Guan, X.
    Li, H.
    Chen, Q.
    Hao, C.
    Li, J.
    Wang, Y.
    Zhang, J.
    Xu, H.
    Liu, C.
    Chu, Y.
    Ma, A.
    VALUE IN HEALTH, 2019, 22 : S405 - S406
12345